September 2008 Volume 8 Number 9
Visit Nature Reviews Cancer online to browse the journal.
Now available at http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0cZl0EB
Please note that you need to be a subscriber to enjoy full text access to
Nature Reviews Cancer online.
To purchase a subscription, please visit: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0a5J0Ew
Alternatively, to recommend a subscription to your library, please visit
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0sRD0Ed
*********************************************************************
Nature Reviews Cancer Impact Factor: 29.19 *
(*Journal Citation Reports, Thomson, 2007)
*********************************************************************
=====================================================================
IT'S NOW FREE TO POST YOUR VACANCY ON
naturejobs.com http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0bZD0EU
It's the breakthrough you've been waiting for. Naturejobs.com —
the scientific jobs board from Nature —
now lets you advertise your vacancy completely FREE OF CHARGE
Go to http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0BGJp0Eb or telephone:
Europe: +44 (0) 20 78434961
US: + 1 800 9897718
=====================================================================
=====================================================================
Nature Reviews Cancer
Focus on Targeting Angiogenesis
There is a continued need for development
of new angiogenesis inhibitors to circumvent
resistance or reduce toxicity, which are often
associated with the clinically approved vascular
endothelial growth factor (VEGF) inhibitors.
Articles in this Focus discuss our evolving
understanding of anti-angiogenic therapy in cancer
and describe some of the most promising new targets.
The Focus is freely available online at
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B1lx0Ev
=====================================================================
=====================================================================
This month's FEATURED article:
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Deborah L. Burkhart and Julien Sage
p671 | doi:10.1038/nrc2399
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uA0ED
=====================================================================
From the editors
p655 | doi:10.1038/nrc2498
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uB0EE
----------------------
RESEARCH HIGHLIGHTS
----------------------
Tumorigenesis: Two-faced
p657 | doi:10.1038/nrc2469
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uC0EF
Oncogenesis: Fusion protein guided by Sat Nav
p658 | doi:10.1038/nrc2473
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uD0EG
Leukaemia: Preparation is everything
p658 | doi:10.1038/nrc2475
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uE0EH
IN THE NEWS
Costly cancer care
p658 | doi:10.1038/nrc2478
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uF0EI
Biomarkers: Finding the needle in the haystack
p659 | doi:10.1038/nrc2474
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uG0EJ
Angiogenesis: VEGFR3 joins the crew
p660 | doi:10.1038/nrc2446
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uH0EK
Tumour suppression: Sharing the limelight
p660 | doi:10.1038/nrc2470
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uI0EL
TRIAL WATCH
Still Sensitive? | Genetically more efficient
p661 | doi:10.1038/nrc2479
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uJ0EM
Translation: Interpreting p53
p662 | doi:10.1038/nrc2471
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uK0EN
Tumorigenesis: Marching to a different drum
p662 | doi:10.1038/nrc2472
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uL0EO
Migration: RAB goes back to RAC
p662 | doi:10.1038/nrc2476
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uM0EP
IN BRIEF
Tumorigenesis | Signalling | Cancer stem cells
p663 | doi:10.1038/nrc2477
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uN0EQ
----------------------
PROGRESS
----------------------
Structural comparisons of class I phosphoinositide 3-kinases
L. Mario Amzel, Chuan-Hsiang Huang, Diana Mandelker, Christoph Lengauer,
Sandra B. Gabelli and Bert Vogelstein
p665 | doi:10.1038/nrc2443
The recent determination of the structure of the class I phosphoinositide
3-kinase PI3K[alpha] has identified important structural differences
between the class 1 PI3Ks. How can this information be used to improve
cancer therapy?
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uO0ER
Article: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uP0ES
=====================================================================
New! WideScreen Human Cancer Panel 1 & 2
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uQ0ET
Accelerate your cancer drug discovery and preclinical studies by
using multiplex immunoassays developed by EMD and RBM. To ensure
gold standard quality data, and to maximize the knowledge gained
from precious, often limited samples, the panels are validated
using CLSI/NCCLS quality standards.
=====================================================================
----------------------
REVIEWS
----------------------
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Deborah L. Burkhart and Julien Sage
p671 | doi:10.1038/nrc2399
Data from human and mouse tumours indicate that loss of the tumour suppressor
gene retinoblastoma (RB) contributes to both cancer initiation and progression.
However, there is much we still need to learn about RB function and the consequences
of its loss.
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uR0EU
Article: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uA0ED
A new MAFia in cancer
Alain Eychene, Nathalie Rocques and Celio Pouponnot
p683 | doi:10.1038/nrc2460
Recent data support an important role for the large Maf proteins in cancer.
This Review discusses the contribution of large Maf family members to oncogenesis.
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uS0EV
Article: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uT0EW
Diet and cancer prevention: the roles of observation and experimentation
Maria Elena Martinez, James R. Marshall and Edward Giovannucci
p694 | doi:10.1038/nrc2441
The evaluation of dietary factors for cancer prevention through observational
epidemiology and experimentation by randomized controlled trials (RCTs) has
given inconsistent and sometimes opposing conclusions. Which study design is
most appropriate?
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uU0EX
Article: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uV0EY
----------------------
PERSPECTIVES
----------------------
OPINION
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Nicholas C. Denko
p705 | doi:10.1038/nrc2468
Aerobic glycolysis, or the 'Warburg effect', is a metabolic switch unique to
tumour cells. But how might this change in tumour cell metabolism confer a
growth advantage?
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uW0EZ
Article: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uX0Ea
OPINION
Tailoring to RB: tumour suppressor status and therapeutic response
Erik S. Knudsen and Karen E. Knudsen
p714 | doi:10.1038/nrc2401
Although RB was first identified as a tumour suppressor over 20 years ago, the
implications of RB loss for tumour biology remain enigmatic. This Perspective
discusses how context-specific consequences of RB inactivation might influence
the response of a tumour to a range of therapeutic agents.
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uY0Eb
Article: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uZ0Ec
INNOVATION
Optical imaging for cervical cancer detection: solutions for a continuing global
problem
Nadhi Thekkek and Rebecca Richards-Kortum
p725 | doi:10.1038/nrc2462
Cervical cancer is the leading cause of cancer death for women in developing countries.
This Perspective discusses how recent advances in optical technologies can improve
the accuracy and availability of cervical cancer screening.
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3ua0Ej
Article: http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3ub0Ek
Corrigendum: The challenge of cancer control in Africa
Rebecca J. Lingwood, Peter Boyle, Alan Milburn, Twalib Ngoma, John Arbuthnott,
Ruth McCaffrey, Stewart H. Kerr and David J. Kerr
p732 | doi:10.1038/nrc2464
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0B3uc0El
=====================================================================
Celebrating 20 years of excellence in cancer research
Oncogene is published weekly and covers the structure
and function of oncogenes. Oncogene publishes a series
of review issues - Oncogene Reviews, which take a closer
look into the most current research and advances that are
impacting the study of cancer. Visit www.nature.com/onc
to read a full FREE issue.
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0BXuC0Eq
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://ealerts.nature.com/cgi-bin24/DM/y/em6M0Xztnp0Hja0Zzu0Eh
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2008 Nature Publishing Group
=====================================================================
